Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.66 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.66 |
| ▸ | APP | P05067 | 12/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.60 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.60 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.60 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.60 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.60 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.60 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945554 | 0.88 | AKR1C3 (0.85) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL1374530 | 0.83 | APP (0.85) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL1372754 | 0.80 | AKR1C3 (1.00) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL3945557 | 0.77 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL29926966 | 0.75 | APP (1.00) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL407631 | 0.75 | APP (1.00) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL15302970 | 0.75 | APP (0.67) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL15307670 | 0.74 | APP (0.79) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL15307672 | 0.72 | APP (0.59) | AKR1C3AKR1C2AKR1C1APPCYP2C19 | |
| SCHEMBL15303088 | 0.72 | APP (0.62) | AKR1C3AKR1C2AKR1C1APPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | claimed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | claimed |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | AKR1C3 813/4885AKR1C2 517/4885AKR1C1 558/4885 |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 454/4885AKR1C2 787/4885AKR1C1 845/4885 |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 484/4885AKR1C2 861/4885AKR1C1 925/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | AKR1C3 454/4885AKR1C2 787/4885AKR1C1 845/4885 |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | SLC6A3, SLC6A2, FKBP5 | AKR1C3 2969/4885AKR1C2 2443/4885AKR1C1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.